Evaluation Summary and Metrics: "Pharmaceutical Pricing and R&D as a Global Public Good"

Evaluator 1, Evaluator 2 and Tabaré Capitán

No 2025-31, The Unjournal Evaluations from The Unjournal

Abstract: We organized two evaluations of the paper: "Pharmaceutical Pricing and R&D as a Global Public Good"[1]. This work considers global drug pricing and whether, relative to the United States, the rest of the world underpays for pharmaceuticals, underfunding R&D as a public good. The authors quantify cross-country differences in drug prices, benchmark these against willingness-to-pay thresholds, and discuss the implications for international pricing negotiations.

Date: 2025-06-16
References: View complete reference list from CitEc
Citations:

Published in The Unjournal

Downloads: (external link)
https://unjournal.pubpub.org/pub/evalsumpharmpricing (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bjn:evalua:evalsumpharmpricing

DOI: 10.21428/d28e8e57.072621d7

Access Statistics for this paper

More papers in The Unjournal Evaluations from The Unjournal
Bibliographic data for series maintained by Davit Jintcharadze ().